Clincosm LogoSign in Get a demo

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

Sponsor
Hadassah Medical Organization (Other)
Overall Status
Unknown status
CT.gov ID
NCT00532519
Collaborator
(none)
1
Location

Study Details

Study Description

Brief Summary

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders.

We hypothesize that a group of these patients may benefit from antidepressant therapy.

Condition or Disease Intervention/Treatment Phase
  • Drug: citalopram (cipralex)
 N/A

Study Design

Study Type:
Interventional
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Inclusion Criteria:

    • prurigo nodularis

    • age: 18-70 years

    • agreed to participate

    Exclusion Criteria:

    • younger than 18 or older than 70

    • pregnant or lactating women

    • chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc.

    • sensitivity to cipralotam

    • psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year

    • use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 : Hadassah Medical Organization, Jerusalem Israel

    Sponsors and Collaborators

    • Hadassah Medical Organization

    Investigators

    • Principal Investigator: liran horev, md, Hadassah Medical Organization
    • Principal Investigator: rena cooper-kazaz, md, Hadassah Medical Organization

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    , ,
    ClinicalTrials.gov Identifier:
    NCT00532519
    Other Study ID Numbers:
    • horcoop-hmo-ctil
    First Posted:
    Sep 20, 2007
    Last Update Posted:
    Sep 20, 2007
    Last Verified:
    Sep 1, 2007
    Additional relevant MeSH terms:
    Prurigo
    Neurodermatitis
    Citalopram

    Study Results

    No Results Posted as of Sep 20, 2007